A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Chronic Myelogenous Leukemia - Chronic Phase Clinical Trial

Official title:
Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Status Completed

Clinical Trial Summary

The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Myelogenous Leukemia - Chronic Phase
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase

Clinical Trial Details

NCT number	NCT04925141
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status	Completed
Phase	Phase 4
Start date	May 10, 2016
Completion date	December 6, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00644878` - Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib	Phase 2
Recruiting	`NCT06082804` - Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia	N/A
Recruiting	`NCT05384587` - Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Phase 2
Active, not recruiting	`NCT04666259` - Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation	Phase 3
Recruiting	`NCT05794880` - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	N/A
Recruiting	`NCT03842696` - Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation	Phase 1/Phase 2